Christopher Goldring, Daniel J. Antoine, Frank Bonner, Jonathan Crozier, Chris Denning, Robert J. Fontana, Neil A. Hanley, David C. Hay, Magnus Ingelman‐Sundberg, Satu Juhila, Neil Kitteringham, Beatriz Silva‐Lima, Alan Norris, Chris Pridgeon, James A. Ross, Rowena Sison Young, Danilo Tagle, Belen Tornesi, Bob van de Water, Richard J. Weaver, Fang Zhang, B. Kevin Park – 24 October 2016 – Current preclinical drug testing does not predict some forms of adverse drug reactions in humans.

Puneeta Tandon, K. Rajender Reddy, Jacqueline G. O'Leary, Guadalupe Garcia‐Tsao, Juan G. Abraldes, Florence Wong, Scott W. Biggins, Benedict Maliakkal, Michael B. Fallon, Ram M. Subramanian, Paul Thuluvath, Patrick S. Kamath, Leroy R. Thacker, Jasmohan S. Bajaj, North American Consortium for the Study of End‐Stage Liver Disease – 24 October 2016 – Identification of patients with cirrhosis at risk for death within 3 months of discharge from the hospital is essential to individualize postdischarge plans.

Sukanta Das, Jaswinder Singh Maras, Md. Shabir Hussain, Shvetank Sharma, Paul David, Sukriti Sukriti, Saggere Muralikrishna Shasthry, Rakhi Maiwall, Nirupama Trehanpati, Tej P. Singh, Shiv Kumar Sarin – 24 October 2016 – Albumin is a potent scavenger of reactive oxygen species (ROS). However, modifications in albumin structure may reduce its antioxidant properties and modulate its immune‐regulatory functions.

Omair Atiq, Jasmin Tiro, Adam C. Yopp, Adam Muffler, Jorge A. Marrero, Neehar D. Parikh, Caitlin Murphy, Katharine McCallister, Amit G. Singal – 24 October 2016 – Although surveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm, downstream harms from follow‐up tests must be weighed against surveillance benefits when determining the value of hepatocellular carcinoma (HCC) screening programs. Our study's aims were to characterize prevalence and correlates of surveillance benefits and harms in cirrhosis patients undergoing HCC surveillance.

Guadalupe Garcia‐Tsao – 22 October 2016

Anika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, Janina Kirschner, Birgit Bremer, Patrick Lehmann, Svenja Hardtke, Katja Deterding, Kerstin Port, Max Westphal, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer – 22 October 2016 – Hepatitis delta virus (HDV) is the most severe form of viral hepatitis. Pegylated interferon alfa (PEG‐IFNα) is effective in only 25%‐30% of patients and is associated with frequent side effects. The aim of this study was to analyze the clinical long‐term outcome of hepatitis delta in relation to different antiviral treatment strategies.

Joanne E. Brady, Danielle K. Liffmann, Anthony Yartel, Natalie Kil, Alex D. Federman, Joseph Kannry, Cynthia Jordan, Omar I. Massoud, David R. Nerenz, Kimberly A. Brown, Bryce D. Smith, Claudia Vellozzi, David B.

Xuehua Piao, Soh Yamazaki, Sachiko Komazawa‐Sakon, Sanae Miyake, Osamu Nakabayashi, Takeyuki Kurosawa, Tetsuo Mikami, Minoru Tanaka, Nico Van Rooijen, Masaki Ohmuraya, Akira Oikawa, Yuko Kojima, Soichiro Kakuta, Yasuo Uchiyama, Masato Tanaka, Hiroyasu Nakano – 22 October 2016 – Tissue‐resident macrophages and bone marrow (BM)‐derived monocytes play a crucial role in the maintenance of tissue homeostasis; however, their contribution to recovery from acute tissue injury is not fully understood.

Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Jennifer T. Wells, Carmen E. Landaverde, Barbara Evans, Anita Howe, Hsueh‐Cheng Huang, Jerry Jing Li, Peggy Hwang, Frank J. Dutko, Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber – 22 October 2016 – Direct‐acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection. Combining DAAs with different mechanisms may allow for shorter treatment durations that are effective across multiple genotypes.

Neehar D. Parikh, Vincent D. Marshall, Amit G. Singal, Hari Nathan, Anna S. Lok, Rajesh Balkrishnan, Vahakn Shahinian – 22 October 2016 – Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC). However, its effectiveness in patients with Child‐Pugh class B cirrhosis and any moderating effects of health system characteristics are unclear. We examined the survival and cost‐effectiveness associated with sorafenib in elderly patients with advanced HCC. We performed an analysis of Medicare beneficiaries with HCC diagnoses from 2007 to 2009.